What is HC Wainwright’s Forecast for DWTX Q1 Earnings?

Dogwood Therapeutics, Inc (NASDAQ:DWTX) – Investment analysts at HC Wainwright lifted their Q1 2026 earnings estimates for Dogwood Therapeutics in a report released on Thursday, March 19th. HC Wainwright analyst S. Lee now expects that the company will post earnings per share of ($0.30) for the quarter, up from their previous forecast of ($0.49). HC Wainwright currently has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($6.43) per share. HC Wainwright also issued estimates for Dogwood Therapeutics’ Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.34) EPS, Q4 2026 earnings at ($0.37) EPS, FY2026 earnings at ($1.33) EPS, FY2027 earnings at ($1.62) EPS, FY2028 earnings at ($1.71) EPS and FY2029 earnings at $0.72 EPS.

Other analysts also recently issued reports about the stock. Wall Street Zen downgraded shares of Dogwood Therapeutics to a “strong sell” rating in a research note on Saturday, December 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Dogwood Therapeutics in a report on Monday, December 22nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $12.00.

Dogwood Therapeutics Stock Performance

Dogwood Therapeutics stock opened at $2.59 on Monday. The company has a 50 day moving average price of $2.95 and a 200 day moving average price of $4.63. Dogwood Therapeutics has a 52 week low of $2.56 and a 52 week high of $9.50. The firm has a market capitalization of $86.51 million, a price-to-earnings ratio of -0.14 and a beta of 1.90.

Dogwood Therapeutics (NASDAQ:DWTX) last released its earnings results on Wednesday, March 18th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($1.22) by $0.96.

Institutional Investors Weigh In On Dogwood Therapeutics

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP acquired a new position in Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned about 0.51% of Dogwood Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 9.05% of the company’s stock.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.